These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25990477)

  • 1. Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study.
    Turan GA; Eskicioglu F; Sivrikoz ON; Cengiz H; Adakan S; Gur EB; Tatar S; Sahin N; Yilmaz O
    Arch Gynecol Obstet; 2015 Nov; 292(5):1163-71. PubMed ID: 25990477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic vitamin D supplementation in ovarian hyperstimulation syndrome: an animal study.
    Turan GA; Eskicioglu F; Sivrikoz ON; Cengiz H; Gur EB; Tatar S; Sahin N; Yilmaz O
    Arch Gynecol Obstet; 2015 Aug; 292(2):421-7. PubMed ID: 25618750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome.
    Şahin N; Apaydın N; Töz E; Sivrikoz ON; Genç M; Turan GA; Cengiz H; Eskicioğlu F
    Arch Gynecol Obstet; 2016 May; 293(5):1101-6. PubMed ID: 26690356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of kisspeptin-54 on ovarian levels of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in an experimental model of ovarian hyperstimulation syndrome (OHSS).
    Birinci H; Vatansever HS; Yüncü M
    Reprod Fertil Dev; 2021 Nov; 33(16):799-809. PubMed ID: 34610858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GnRH Agonist Triggering Modulates PEDF to VEGF Ratio Inversely to hCG in Granulosa Cells.
    Miller I; Chuderland D; Ron-El R; Shalgi R; Ben-Ami I
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1428-36. PubMed ID: 26308290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myoinositol
    Rajasekaran K; Malhotra N; Mahey R; Khadgawat R; Kalaivani M
    Gynecol Endocrinol; 2022 Feb; 38(2):140-147. PubMed ID: 34590929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model.
    Quintana R; Kopcow L; Marconi G; Young E; Yovanovich C; Paz DA
    Fertil Steril; 2008 Oct; 90(4 Suppl):1511-6. PubMed ID: 18166186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
    Saylan A; Arioz DT; Koken T; Dilek H; Saylan F; Yilmazer M
    Acta Obstet Gynecol Scand; 2010 May; 89(5):692-9. PubMed ID: 20423279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of pigment epithelium-derived factor in the pathophysiology and treatment of ovarian hyperstimulation syndrome in mice.
    Chuderland D; Ben-Ami I; Kaplan-Kraicer R; Grossman H; Ron-El R; Shalgi R
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E258-66. PubMed ID: 23295464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between resveratrol and cabergoline in preventing ovarian hyperstimulation syndrome in a rat model.
    Kasap E; Turan GA; Eskicioğlu F; Cengiz H; Gur EB; Sivrikoz ON; Genc M; Yılmaz O
    Gynecol Endocrinol; 2016 Aug; 32(8):634-640. PubMed ID: 26939766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of GnRH-antagonist, mifepristone and letrozole on preventing ovarian hyperstimulation syndrome in rat model.
    Luo J; Qi Q; Chen Y; Wang Y; Xie Q
    Reprod Biomed Online; 2021 Feb; 42(2):291-300. PubMed ID: 33249057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
    Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
    Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model.
    Hortu I; Karadadas E; Ozceltik G; Tavmergen E; Tavmergen Goker EN; Yigitturk G; Erbas O
    Arch Gynecol Obstet; 2021 Apr; 303(4):1099-1108. PubMed ID: 33140116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
    van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
    Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Zhang J; Huang J; He X; Li N; Miao Y; Li B; Shao X; Wang N
    Gynecol Endocrinol; 2022 Apr; 38(4):318-323. PubMed ID: 35285758
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Zhang J; Huang J; He X; Li N; Miao Y; Li B; Shao X; Wang N
    Gynecol Endocrinol; 2022 Feb; 38(2):170-175. PubMed ID: 34964405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Dual Role of PEDF in the Pathogenesis of OHSS: Negating Both Angiogenic and Inflammatory Pathways.
    Miller I; Chuderland D; Grossman H; Ron-El R; Ben-Ami I; Shalgi R
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4699-4709. PubMed ID: 27680872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Montelukast is effective in preventing of ovarian hyperstimulation syndrome; an experimental study.
    Eskicioğlu F; Turan GA; Sivrikoz ON; Cengiz H; Zafer A; Akan Z; Sahin N; Yilmaz O; Yeşil H; Vatansever S
    Ginekol Pol; 2015 Aug; 86(8):566-73. PubMed ID: 26492704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inositol for subfertile women with polycystic ovary syndrome.
    Showell MG; Mackenzie-Proctor R; Jordan V; Hodgson R; Farquhar C
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012378. PubMed ID: 30570133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome.
    Di Pietro M; Pascuali N; Scotti L; Irusta G; Bas D; May M; Tesone M; Abramovich D; Parborell F
    Mol Hum Reprod; 2017 Jun; 23(6):417-427. PubMed ID: 28379469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.